Valuation: TAUNS Laboratories,Inc.

Market Cap 49.56B 307M 269M 247M 230M 436M 29.26B 443M 2.96B 1.15B 14.38B 1.15B 1.13B P/E 2025
8.67x
P/E 2026 * 9.35x
Enterprise Value 56.39B 350M 306M 281M 262M 497M 33.29B 504M 3.37B 1.31B 16.36B 1.31B 1.28B EV / Sales 2025
3.23x
EV / Sales 2026 * 3.9x
Free-Float
29.82%
Yield 2025
5.2%
Yield 2026 * 7.59%
1 week-4.12%
Current month-1.48%
1 month-4.91%
3 months-7.55%
6 months-8.64%
Current year-8.64%
1 week 463
Extreme 463
482
1 month 463
Extreme 463
492
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 30/04/2014
Director of Finance/CFO 66 31/10/2018
Corporate Officer/Principal 39 30/06/2022
Director TitleAgeSince
Director/Board Member 51 30/04/2014
Director/Board Member 66 31/08/2020
Director/Board Member 53 31/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.12%-10.58% - 307M
-1.63%+12.57%+232.63%+375.33% 22.27B
-1.27%-2.18%-41.43%-25.85% 9.4B
+0.85%+0.08%+36.65%+31.18% 7.15B
-2.40%-1.08%-31.05% - 5.17B
+0.23%+4.51%-18.49%-28.11% 5.13B
-0.10%+6.15%+199.85%-31.25% 4.95B
+0.61%+2.14%-22.68%-25.19% 4.23B
-1.07%-0.09%+81.93%+87.31% 4.1B
+2.89%+8.01%-17.46%-42.49% 2.61B
Average -0.19%+2.74%+40.94%+42.62% 6.53B
Weighted average by Cap. -0.74%+6.74%+91.52%+136.69%

Financials

2025 2026 *
Net sales 19.06B 118M 103M 94.95M 88.5M 168M 11.25B 170M 1.14B 443M 5.53B 444M 434M 14.76B 91.49M 79.98M 73.51M 68.51M 130M 8.71B 132M 882M 343M 4.28B 343M 336M
Net income 6.5B 40.3M 35.23M 32.38M 30.18M 57.24M 3.84B 58.11M 389M 151M 1.89B 151M 148M 5.2B 32.25M 28.19M 25.91M 24.15M 45.81M 3.07B 46.5M 311M 121M 1.51B 121M 118M
Net Debt 6.83B 42.34M 37.02M 34.02M 31.71M 60.14M 4.03B 61.06M 408M 159M 1.98B 159M 156M 7.99B 49.57M 43.33M 39.82M 37.12M 70.4M 4.72B 71.47M 478M 186M 2.32B 186M 182M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
03/07/26 JP¥465.00 0.00% 344,600
02/07/26 JP¥465.00 0.00% 258,000
01/07/26 JP¥465.00 -1.48% 278,800
30/06/26 JP¥472.00 +0.64% 245,300
29/06/26 JP¥469.00 -3.30% 540,100
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
465.00JPY
Average target price
420.00JPY
Spread / Average Target
-9.68%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock